Overview

Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan

Status:
Completed

Trial end date:
2016-10-17

Target enrollment:

Participant gender:

Summary

To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals